Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physicians

Clinical Trial Grant

Duke Scholars

Principal Investigator Carey Kernodle Anders Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Hoosier Cancer Research Network, Inc

Start Date

February 10, 2022

End Date

January 31, 2027

Administered By

Duke Cancer Institute

Awarded By

Hoosier Cancer Research Network, Inc

Start Date

February 10, 2022

End Date

January 31, 2027